Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose open-label pharmacokinetic study of CHF 5993 pMDI in adolescent asthma
2019-002238-35Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of beclomethasone dipropionate, formoterol and glycopyrronium in asthma (2 cohorts), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Systemic exposure of B17MP, formoterol and glycopyrronium bromide and Efficacy and safety endpoints. Started Oct 2019; status: completed.
02
Drugs
beclomethasone dipropionateformoterolglycopyrronium
03
Conditions
asthma
Beyond the preview
Go deeper on 2019-002238-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002238-35.